Frequency, risk factors, prognosis, and genetic polymorphism of the cyclooxygenase-1 gene for aspirin resistance in elderly chinese patients with cardiovascular disease

Gerontology

Volumn 59, Issue 2, 2013, Pages 122-131

  Fan, Li ^a   Cao, Jian ^a   Liu, Lin ^a   Li, Xiaoli ^a   Hu, Guoliang ^a   Hu, Yixin ^a   Zhu, Bingpo ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Aspirin resistance; Cardiovascular disease; Cyclooxygenase 1 gene; Elderly Chinese patients; Frequency; Prognosis; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID;

AGED; ALLELE; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CHINESE; CONTROLLED STUDY; CYCLOOXYGENASE 1 GENE; FEMALE; FOLLOW UP; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; THROMBOELASTOGRAPHY; THROMBOELASTOGRAPHY PLATELET MAPPING ASSAY;

EID: 84874788096     PISSN: 0304324X     EISSN: 14230003     Source Type: Journal    
DOI: 10.1159/000342489     Document Type: Article

References (48)

1. Yazdanyar A, Newman AB. The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs. Clin Geriatr Med 2009; 25: 563-577
2. Zheng Y SR, Kwan T, Yu C, Kwan J, Chen SL, Hu D. Evolving cardiovascular disease prevalence, mortality, risk factors, and the metabolic syndrome in China. Clin Cardiol 2009; 32: 491-497
3. Collaboration AT. Collaborative meta-Analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86
4. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-965
5. Chen WH, Cheng X, Lee PY, Ng W, Kwok JY, Tse HF, Lau CP. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 2007; 120: 631-635
6. Feher G, Feher A, Pusch G, Koltai K, Tibold A, Gasztonyi B, Papp E, Szapary L, Kesmarky G, Toth K. Clinical importance of aspirin and clopidogrel resistance. World J Cardiol 2010; 2: 171-186
7. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin 'resistance' and risk of cardiovascular morbidity: systematic review and meta-Analysis. BMJ 2008; 336: 195-198
8. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-Analysis. Arch Intern Med 2007; 167: 1593-1599
9. Crescente M, Di Castelnuovo A, Iacoviello L, Vermylen J, Cerletti C, de Gaetano G. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100: a systematic review. Thromb Haemost 2008; 99: 14-26
10. Reny JL, De Moerloose P, Dauzat M, Fontana P. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-Treated cardiovascular patients: a systematic review and meta-Analysis. J Thromb Haemost 2008; 6: 444-450
11. Kasotakis G, Pipinos II, Lynch TG. Current evidence and clinical implications of aspirin resistance. J Vasc Surg 2009; 50: 1500-1510
12. Feher G, Feher A, Pusch G, Koltai K, Tibold A, Gasztonyi B, Papp E, Szapary L, Kesmarky G, Toth K. Clinical importance of aspirin and clopidogrel resistance. World J Cardiol 2010; 2: 171-186
13. Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus. Diabetologia 2008; 51: 385-390
14. Schafer AI. Genetic and acquired determinants of individual variability of response to antiplatelet drugs. Circulation 2003; 108: 910-911
15. Tantry US, Mahla E, Gurbel PA. Aspirin resistance. Prog Cardiovasc Dis 2009; 52: 141-152
16. Cao J, Liu L, Fan L, Chen T, Hu G, Hu Y, Zhu B, Li J, Wang H, Li X. The prevalence, risk factors and prognosis of aspirin resistance in elderly male patients with cardiovascular disease. Aging Male 2012; 15: 140-147
17. Tantry US BK, Gurbel PA. Overestimation of platelet aspirin resistance detection by thromboleastograph platelet mapping and validation by conventional aggreagometry using arachidonic acid stimulation. J Am Coll Cardiol 2005; 1705-1709
18. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28: 1702-1708
19. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: 959-969
20. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) - developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007; 116:e148-e304
21. Gurbel PA, Bilden KP, Di Chiara J, Newcomer J, Weng J, Neerchal W, Gesheff NK, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007; 115: 3156-3164
22. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005; 46: 1705-1709
23. Carroll RC, Worthington RE, Craft RM, Snider CC, Dakin PA, Wortham DC, Scott J, Jarrett A. Post interventional cardiology urinary thromboxane correlates with PlateletMapping detected aspirin resistance. Thromb Res 2010; 125:e118-e122
24. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-235
25. Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002; 108: 37-42
26. Ozben S, Ozben B, Tanrikulu AM, Ozer F, Ozben T. Aspirin resistance in patients with acute ischemic stroke. J Neurol 2011; 258: 1879-1986
27. Nidhinandana S, Changchit S. Prevalence of aspirin resistance in stroke patients in Phramongkutklao Hospital. J Med Assoc Thai 2011; 93(suppl 6):S51-S54
28. Lee JH, Cha JK, Lee SJ, Ha SW, Kwon SU. Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial. Eur J Neurol 2009; 17: 434-442
29. Englyst NA, Horsfield G, Kwan J, Byrne CD. Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity. J Cereb Blood Flow Metab 2008; 28: 1196-1203
30. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder: a pilot-study including 180 post-stroke patients. Thromb Res 1993; 71: 397-403
31. Watala C, Ulicna O, Golanski J, Nocun M, Waczulikova I, Markuszewski L, Drzewoski J. High glucose contributes to aspirin insensitivity in streptozotocin-diabetic rats: a multiparametric aggregation study. Blood Coagul Fibrinolysis 2006; 17: 113-124
32. Watala C, Golanski J, Pluta J, Boncler M, Rozalski M, Luzak B, Kropiwnicka A, Drzewoski J. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin) - its relation to metabolic control. Thromb Res 2004; 113: 101-113
33. Pulcinelli FM, Riondino S. More on aspirin resistance: position paper of the Working Group on Aspirin Resistance - proposal for a laboratory test guiding algorithm. J Thromb Haemost 2006; 4: 485-487
34. Ertugrul DT, Tutal E, Yildiz M, Akin O, Yalcin AA, Ure OS, Yilmaz H, Yavuz B, Deveci OS, Ata N, Kucukazman M. Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus. J Clin Endocrinol Metab 2010; 95: 2897-901
35. Cohen HW, Crandall JP, Hailpern SM, Billett HH. Aspirin resistance associated with HbA1c and obesity in diabetic patients. J Diabetes Complications 2008; 22: 224-228
36. Dropinski J, Jakiela B, Sanak M, Wegrzyn W, Biernat M, Dziedzina S, Plutecka H, Szczeklik A. The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin. Thromb Haemost 2007; 98: 201-209
37. Holmes AS, Chirkov YY, Willoughby SR, Poropat S, Pereira J, Horowitz JD. Preservation of platelet responsiveness to nitroglycerine despite development of vascular nitrate tolerance. Br J Clin Pharmacol 2005; 60: 355-363
38. Tassies D. Pharmacogenetics of antithrombotic drugs. Curr Pharm Des 2006; 12: 2425-2435
39. Oh SH, Kim YH, Park SM, Cho SH, Park JS, Jang AS, Park SW, Uh ST, Lee YM, Kim MK, Choi IS, Hong CS, Lee YW, Lee JY, Choi BW, Park BL, Shin HD, Park CS. Association analysis of thromboxane A synthase 1 gene polymorphisms with aspirin intolerance in asthmatic patients. Pharmacogenomics 2011; 12: 351-363
40. Lev EI, Patel RT, Guthikonda S, Lopez D, Bray PF, Kleiman NS. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thromb Res 2007; 119: 355-360
41. Goodman T, Sharma P, Ferro A. The genetics of aspirin resistance. Int J Clin Pract 2007; 61: 826-834
42. Agúndez JA, Martinez C, Perez-Sala D, Carballo M, Torres MJ, Garcia-Martin E. Pharmacogenomics in aspirin intolerance. Curr Drug Metab 2009; 10: 998-1008
43. Arisawa T, Tahara T, Shibata T, Nagasaka M, Nakamura M, Kamiya Y, Fujita H, Yoshioka D, Arima Y, Okubo M, Hirata I, Nakano H. Association between genetic polymorphisms in the cyclooxygenase-1 gene promoter and peptic ulcers in Japan. Int J Mol Med 2007; 20: 373-378
44. Arisawa T, Tahara T, Shibata T, Nagasaka M, Nakamura M, Kamiya Y, Fujita H, Yoshioka D, Arima Y, Okubo M, Hirata I, Nakano H. Genetic polymorphisms of cyclooxygenase-1 (COX-1) are associated with functional dyspepsia in Japanese women. J Womens Health (Larchmt) 2008; 17: 1039-1043
45. Gurbel PA, Bilden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, Gesheff T, Chaganti SK, Etherington A, Tantry US. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007; 115: 3156-3164
46. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502
47. Zhang Z, Foster JK, Kolm P, Jurkovitz CT, Parker KM, Murrah NV, Anderson GT, Douglas JS Jr, Weintraub WS. Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the Cilostazol for RESTenosis (CREST) trial. Am Heart J 2006; 152: 770-776
48. Mahoney EM, Wang K, Arnold SV, Proskorovsky I, Wiviott S, Antman E, Braunwald E, Cohen DJ. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in myocardial infarction TRITON-TIMI 38. Circulation 2010; 121: 71-79